Maze Therapeutics (MAZE) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by the CEO and Chairperson, emphasizing the benefits of a virtual format for broader participation.

• General Counsel introduced as Secretary to keep minutes; Board members, CFO, legal counsel, and Inspector of Elections present.

Shareholder proposals

• Two proposals presented: election of two Class I Directors for three-year terms and ratification of Ernst & Young LLP as independent auditor for 2026.

• Board recommended voting in favor of both proposals.

Q&A with stakeholders

• Stockholders allowed to submit one written question each, limited to 10 minutes for Q&A, but no questions were received.